PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Description

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.

Conditions

Pancreatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Scottsdale

HonorHealth Medical Group, Scottsdale, Arizona, United States, 85258-4566

Milwaukee

Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Has received chemotherapy and/or radiation within three years prior to study enrollment.
  • 2. Has any previous history of another malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in situ carcinoma of the cervix or localized prostate cancer with normal prostate specific antigen) within three years of study enrollment.
  • 3. Uncontrolled comorbidities including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina, unstable cardiac arrhythmias, psychiatric illness, excessive obesity (BMI \>55) or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
  • 4. Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • 5. Pregnant or breastfeeding patients or any patient with childbearing potential not using contraception four weeks prior to treatment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medical College of Wisconsin,

Kathleen K Christians, MD, PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

2027-06